免疫疗法
癌症
癌症研究
生物标志物
免疫系统
免疫检查点
抗体
作者
Makoto Nakao,Hideki Muramatsu,Yusuke Kagawa,Yuto Suzuki,Yusuke Sakai,Ryota Kurokawa,Kohei Fujita,Hidefumi Sato
出处
期刊:Anticancer Research
[Anticancer Research USA Inc.]
日期:2017-07-01
卷期号:37 (7): 3781-3786
被引量:12
标识
DOI:10.21873/anticanres.11753
摘要
BACKGROUND/AIM It remains challenging to select patients with non-small cell carcinoma (NSCLC) for nivolumab monotherapy. We evaluated whether early termination of nivolumab monotherapy correlated with pretreatment neutrophil/lymphocyte ratio (NLR) and prognostic nutritional index (PNI). PATIENTS AND METHODS Twenty patients received nivolumab monotherapy for NSCLC with wild-type epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) during 2016. Early termination and continued therapy were defined as ≤5 and ≥6 cycles of monotherapy, respectively. RESULTS Early termination and continued therapy groups included 9 and 11 patients, respectively. High pretreatment NLR and low pretreatment PNI were significantly associated with early termination of nivolumab, both in an overall analysis (p<0.001 and p=0.016) and in subgroup analyses of patients with performance scores of 0-1 and ≥30 days of pretreatment drug holidays. CONCLUSION High NLR and low PNI were associated with early termination of nivolumab monotherapy, suggesting they might be useful biomarkers for treatment selection.
科研通智能强力驱动
Strongly Powered by AbleSci AI